Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Amryt Pharma plc (AMYT)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 days ago | GlobeNewsWire
6 days ago | GlobeNewsWire
a week ago | Proactive Investors
a week ago | GlobeNewsWire
a week ago | Proactive Investors
2 weeks ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | GlobeNewsWire
2 months ago | GlobeNewsWire
2 months ago | Proactive Investors
About:
Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.
Sector:
HealthcareIndustry:
Drug Manufacturers—Specialty & GenericAddress:
Amryt Pharma plc Dept 920A 196 High Road Wood Green London N22 8HH United KingdomWebsite:
Home